Theravance Biopharma’s (TBPH) “Neutral” Rating Reiterated at BTIG Research

BTIG Research reissued their neutral rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research report report published on Thursday,Benzinga reports.

Several other equities analysts also recently weighed in on TBPH. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their target price for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 7th. JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. Finally, Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. Eight research analysts have rated the stock with a Hold rating, According to data from MarketBeat, Theravance Biopharma presently has a consensus rating of “Hold” and a consensus price target of $19.40.

Theravance Biopharma Stock Performance

TBPH opened at $17.03 on Thursday. The firm’s 50 day simple moving average is $16.97 and its two-hundred day simple moving average is $16.48. The company has a market capitalization of $884.18 million, a PE ratio of 16.86 and a beta of 0.25. Theravance Biopharma has a 1-year low of $13.08 and a 1-year high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The business had revenue of $20.73 million for the quarter, compared to the consensus estimate of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. Equities analysts forecast that Theravance Biopharma will post 1.56 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Eli Samaha sold 273,871 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $17.23, for a total value of $4,718,797.33. Following the completion of the transaction, the insider owned 9,237,279 shares of the company’s stock, valued at $159,158,317.17. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total value of $226,737.42. Following the sale, the senior vice president owned 213,476 shares of the company’s stock, valued at $3,635,496.28. This represents a 5.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 350,011 shares of company stock worth $6,016,830 over the last 90 days. Company insiders own 7.65% of the company’s stock.

Institutional Trading of Theravance Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Theravance Biopharma by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock valued at $15,960,000 after purchasing an additional 124,658 shares during the last quarter. Pacer Advisors Inc. purchased a new position in shares of Theravance Biopharma during the fourth quarter valued at about $6,342,000. Bank of America Corp DE increased its holdings in shares of Theravance Biopharma by 78.2% in the first quarter. Bank of America Corp DE now owns 189,155 shares of the biopharmaceutical company’s stock worth $3,070,000 after purchasing an additional 82,978 shares during the last quarter. Wedge Capital Management L L P NC purchased a new stake in shares of Theravance Biopharma in the second quarter worth about $2,190,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Theravance Biopharma in the first quarter worth about $2,076,000. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.